NCT04858412

Study of HMB-enriched Amino Acid Supplementation in Patients With Alcoholic Liver Disease and COVID-19

Evaluate the Molecular Mechanisms of HMB-enriched Amino Acid Supplement to Reverse Muscle Loss in Patients With Alcoholic Liver Disease and COVID-19

• Status: Recruiting
• Phase: N/A
• Study type: Interventional
• Enrollment: 48 (estimated)
• Sponsor: The Cleveland Clinic · Academic / Other
• Sex: All
• Age: 21 Years
• Healthy volunteers: Not accepted

Summary

Patients with COVID-19 and comorbidities including alcohol associated liver disease (ALD) are at risk for severe illness and abrupt or sudden clinical deterioration with ventilatory failure. â-hydroxy â-methyl butyrate (HMB), a non-nitrogenous leucine metabolite with anabolic properties, increases muscle mass and contractile function and enhances immune function. We aim to study the natural course of COVID-19 in patients with ALD and test whether HMB can affect ventilatory deterioration and improve short and long-term morbidity, mortality, and recovery from critical illness in symptomatic COVID-19 patients with ALD.

Conditions

• Alcoholic Liver Disease
• COVID 19 Pneumonia

Interventions

Type	Name	Description
DIETARY_SUPPLEMENT	β-hydroxy β-methyl butyrate (HMB) enriched amino acid	β-hydroxy β-methyl butyrate (HMB) is a non-nitrogenous leucine metabolite with anabolic properties.
DIETARY_SUPPLEMENT	Balanced amino acid	Balanced amino acid is the balanced mixture of the various essential amino acids.

Timeline

• Start date: 2021-04-01
• Primary completion: 2026-12-31
• Completion: 2026-12-31
• First posted: 2021-04-26
• Last updated: 2025-11-25

Locations

1 site across 1 country: United States